1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents

Biological evaluation and molecular docking

Manjunatha Bhat, G. K. Nagaraja, Reshma Kayarmar, K. Sreedhara Ranganath Pai, Subhankar Biswas, R. Mohammed Shafeeullah

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A series of newcompounds3-{5-methyl-1-[2-methyl-3-(trifluoromethyl) phenyl/substituted phenyl]-1H-1,2,3-triazol- 4-yl}-1-(aryl)-1H-pyrazole-4-carbaldehydes(5a-n)wassynthesized by a Vilsmeier-Haackformylation reaction of 4- {(1E)-1-[2-(aryl) hydrazinylidene]ethyl}-5-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl/substituted phenyl]-1H- 1,2,3-triazole (4a-n) with Phosphorous oxychloride-DMF mixture. The newly synthesized compounds were elucidated by their spectral studies. Further, the in-vitro anti-cancer activities of the newly synthesized compounds(5a-n)were carried out against breast cancer cell lines MCF-7 and MDA-MB-231. The compounds 5c, 5f, 5g, 5j, 5m and 5n exhibits significant activities against both the cell lines MCF-7 and MDA-MB-231 with IC50 values in the range of 6.8-9.8 μM and 11.1-14.1 μM respectively. The anti-cancer results were further supported by the in-silico molecular docking studies for the inhibition of Epidermal growth factor receptor (EGFR) kinase (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK) respectively, showed minimum binding energies and good affinities towards the active pockets comparable with the standard drug Toremifene. Thus, they may be considered as good inhibitors of EGFR kinase domain (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK).

Original languageEnglish
Pages (from-to)200-221
Number of pages22
JournalDer Pharma Chemica
Volume8
Issue number19
Publication statusPublished - 2016

Fingerprint

Epidermal Growth Factor Receptor
Estrogen Receptors
Toremifene
Cells
Derivatives
Triazoles
Binding energy
Pharmaceutical Preparations
pyrazole

All Science Journal Classification (ASJC) codes

  • Chemistry(all)

Cite this

Bhat, M., Nagaraja, G. K., Kayarmar, R., Sreedhara Ranganath Pai, K., Biswas, S., & Mohammed Shafeeullah, R. (2016). 1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents: Biological evaluation and molecular docking. Der Pharma Chemica, 8(19), 200-221.
Bhat, Manjunatha ; Nagaraja, G. K. ; Kayarmar, Reshma ; Sreedhara Ranganath Pai, K. ; Biswas, Subhankar ; Mohammed Shafeeullah, R. / 1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents : Biological evaluation and molecular docking. In: Der Pharma Chemica. 2016 ; Vol. 8, No. 19. pp. 200-221.
@article{55e099d3519241d4b234666a93282b11,
title = "1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents: Biological evaluation and molecular docking",
abstract = "A series of newcompounds3-{5-methyl-1-[2-methyl-3-(trifluoromethyl) phenyl/substituted phenyl]-1H-1,2,3-triazol- 4-yl}-1-(aryl)-1H-pyrazole-4-carbaldehydes(5a-n)wassynthesized by a Vilsmeier-Haackformylation reaction of 4- {(1E)-1-[2-(aryl) hydrazinylidene]ethyl}-5-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl/substituted phenyl]-1H- 1,2,3-triazole (4a-n) with Phosphorous oxychloride-DMF mixture. The newly synthesized compounds were elucidated by their spectral studies. Further, the in-vitro anti-cancer activities of the newly synthesized compounds(5a-n)were carried out against breast cancer cell lines MCF-7 and MDA-MB-231. The compounds 5c, 5f, 5g, 5j, 5m and 5n exhibits significant activities against both the cell lines MCF-7 and MDA-MB-231 with IC50 values in the range of 6.8-9.8 μM and 11.1-14.1 μM respectively. The anti-cancer results were further supported by the in-silico molecular docking studies for the inhibition of Epidermal growth factor receptor (EGFR) kinase (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK) respectively, showed minimum binding energies and good affinities towards the active pockets comparable with the standard drug Toremifene. Thus, they may be considered as good inhibitors of EGFR kinase domain (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK).",
author = "Manjunatha Bhat and Nagaraja, {G. K.} and Reshma Kayarmar and {Sreedhara Ranganath Pai}, K. and Subhankar Biswas and {Mohammed Shafeeullah}, R.",
note = "cited By 1",
year = "2016",
language = "English",
volume = "8",
pages = "200--221",
journal = "Der Pharma Chemica",
issn = "0975-413X",
publisher = "Scholars Research Library",
number = "19",

}

Bhat, M, Nagaraja, GK, Kayarmar, R, Sreedhara Ranganath Pai, K, Biswas, S & Mohammed Shafeeullah, R 2016, '1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents: Biological evaluation and molecular docking', Der Pharma Chemica, vol. 8, no. 19, pp. 200-221.

1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents : Biological evaluation and molecular docking. / Bhat, Manjunatha; Nagaraja, G. K.; Kayarmar, Reshma; Sreedhara Ranganath Pai, K.; Biswas, Subhankar; Mohammed Shafeeullah, R.

In: Der Pharma Chemica, Vol. 8, No. 19, 2016, p. 200-221.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 1,2,3-Triazolyl pyrazole derivatives as anti-cancer agents

T2 - Biological evaluation and molecular docking

AU - Bhat, Manjunatha

AU - Nagaraja, G. K.

AU - Kayarmar, Reshma

AU - Sreedhara Ranganath Pai, K.

AU - Biswas, Subhankar

AU - Mohammed Shafeeullah, R.

N1 - cited By 1

PY - 2016

Y1 - 2016

N2 - A series of newcompounds3-{5-methyl-1-[2-methyl-3-(trifluoromethyl) phenyl/substituted phenyl]-1H-1,2,3-triazol- 4-yl}-1-(aryl)-1H-pyrazole-4-carbaldehydes(5a-n)wassynthesized by a Vilsmeier-Haackformylation reaction of 4- {(1E)-1-[2-(aryl) hydrazinylidene]ethyl}-5-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl/substituted phenyl]-1H- 1,2,3-triazole (4a-n) with Phosphorous oxychloride-DMF mixture. The newly synthesized compounds were elucidated by their spectral studies. Further, the in-vitro anti-cancer activities of the newly synthesized compounds(5a-n)were carried out against breast cancer cell lines MCF-7 and MDA-MB-231. The compounds 5c, 5f, 5g, 5j, 5m and 5n exhibits significant activities against both the cell lines MCF-7 and MDA-MB-231 with IC50 values in the range of 6.8-9.8 μM and 11.1-14.1 μM respectively. The anti-cancer results were further supported by the in-silico molecular docking studies for the inhibition of Epidermal growth factor receptor (EGFR) kinase (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK) respectively, showed minimum binding energies and good affinities towards the active pockets comparable with the standard drug Toremifene. Thus, they may be considered as good inhibitors of EGFR kinase domain (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK).

AB - A series of newcompounds3-{5-methyl-1-[2-methyl-3-(trifluoromethyl) phenyl/substituted phenyl]-1H-1,2,3-triazol- 4-yl}-1-(aryl)-1H-pyrazole-4-carbaldehydes(5a-n)wassynthesized by a Vilsmeier-Haackformylation reaction of 4- {(1E)-1-[2-(aryl) hydrazinylidene]ethyl}-5-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl/substituted phenyl]-1H- 1,2,3-triazole (4a-n) with Phosphorous oxychloride-DMF mixture. The newly synthesized compounds were elucidated by their spectral studies. Further, the in-vitro anti-cancer activities of the newly synthesized compounds(5a-n)were carried out against breast cancer cell lines MCF-7 and MDA-MB-231. The compounds 5c, 5f, 5g, 5j, 5m and 5n exhibits significant activities against both the cell lines MCF-7 and MDA-MB-231 with IC50 values in the range of 6.8-9.8 μM and 11.1-14.1 μM respectively. The anti-cancer results were further supported by the in-silico molecular docking studies for the inhibition of Epidermal growth factor receptor (EGFR) kinase (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK) respectively, showed minimum binding energies and good affinities towards the active pockets comparable with the standard drug Toremifene. Thus, they may be considered as good inhibitors of EGFR kinase domain (PDB ID: 2A91) and human estrogen receptor (PDB ID: 2IOK).

UR - http://www.scopus.com/inward/record.url?scp=84999176879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999176879&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 200

EP - 221

JO - Der Pharma Chemica

JF - Der Pharma Chemica

SN - 0975-413X

IS - 19

ER -